

Glicothera BV Launches to Advance First-in-Class Neuroprotective Therapy for Stroke

November, 2025 – Schijndel, The Netherlands – Glicothera BV, a neuroprotective therapeutics company, today announced its official launch as a joint venture between Galenicap BV and Neurevo GmbH. The company combines Galenicap’s proven formulation and IP innovation capabilities with Neurevo’s deep scientific and medical expertise in neurology to advance its lead program, GLCP-086-1, a first-in-class therapy in development for acute neuroprotection following ischemic stroke.

Ischemic stroke remains a leading cause of death and disability worldwide, with 30–50% of patients unable to regain functional independence despite reperfusion treatments such as thrombolysis and thrombectomy. This persistent neuronal damage – particularly in the penumbra region surrounding the infarct – highlights a critical gap in current care.

Glicothera’s lead candidate, GLCP-086-1, is a New Chemical Entity (NCE) designed to protect mitochondria and promote neuronal survival through a triple mechanism targeting oxidative stress, calcium overload, and energy restoration. GLCP-086-1 has shown robust neuroprotective effects in multiple preclinical stroke models, including a large-animal study demonstrating significant infarct size reduction. Formulation development and stability testing are complete, and the program is now advancing through GLP toxicology and IND-enabling studies, supported by positive scientific advice from the German regulatory authority (BfArM).

“Glicothera was founded to address the long-standing absence of neuroprotective treatments in stroke,” said Bernd van Buuren, Chief Executive Officer. “Our mission is to translate robust preclinical science into a therapy that meaningfully improves recovery and long-term outcomes in stroke patients. With a validated mechanism, positive regulatory feedback, and a seasoned development team, we are well positioned to move GLCP-086-1 toward clinical evaluation.”

“GLCP-086-1 represents a new therapeutic approach to neuroprotection,” added Francisco Pan-Montojo Puga, Co-founder and Chief Scientific Officer. “By supporting mitochondrial function and reducing oxidative stress, GLCP-086-1 directly addresses the neuronal damage that current stroke interventions fail to prevent. Our data and regulatory alignment give us confidence in its clinical potential.”

Hans Platteeuw, Co-founder and Chief Development Officer, commented: “Our program is scientifically validated and operationally de-risked. With GMP-quality investigational drug material already available, we are preparing for IND-enabling toxicology and first-in-human studies. The BfArM’s guidance provides a clear path toward clinical proof-of-concept.”

About Glicothera BV

Glicothera BV is a neuroprotective therapeutics company advancing GLCP-086-1, a first-in-class mitochondrial-targeted therapy for acute neuroprotection in ischemic stroke. Founded as a joint venture between Galenicap BV and Neurevo GmbH, Glicothera integrates deep expertise in formulation development, IP generation, and translational neuroscience. With a leadership team that has delivered over 100 drug formulation projects and more than 40 marketed products, the company combines scientific rigor with proven development execution.

Glicothera is currently raising €7.5 million to complete IND-enabling studies and initiate Phase I/II clinical trials, and is open to early-stage partnering discussions with strategic pharmaceutical investors.

About Galenicap BV

Galenicap is a pharmaceutical innovator focused on Value-Added Medicines (VAM), transforming known molecules into IP-protected therapeutics with enhanced clinical and commercial value. The company manages 12 active VAM programs across various therapeutic indications, including oncology, CNS, stroke, women's health and infectious diseases.

About Neurevo GmbH

Neurevo is a Munich-based biotech company developing first-in-class neuroprotective treatments targeting mitochondrial function. Its pipeline addresses neurological disorders including ALS, Parkinson's disease, and stroke.

For partnership and investment inquiries, please contact:

Bernd van Buuren, PhD

CEO, Glicothera BV

Email: bernd.van.buuren@galenicap.com

Phone: +31 6 481 056 58

##

Forward-Looking Statement

This press release contains forward-looking statements subject to risks and uncertainties. Actual results may differ materially due to factors such as regulatory outcomes, clinical trial results, and market conditions. Glicothera BV undertakes no obligation to update forward-looking statements unless required by law.